March 21st 2023
A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.
March 14th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate CancerSeptember 18th 2022
Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Apalutamide Plus ADT Demonstrates Promised in High-Risk Biochemically Relapsed Prostate CancerSeptember 12th 2022
Findings from the phase 3 PRESTO trial indicated that patients with high-risk biochemically recurrent prostate cancer may derive benefit from treatment with androgen deprivation therapy intensification and apalutamide.
MFS Benefit Derived From Long-Course Therapy With ADT Plus Radiotherapy After Surgery in Prostate CancerSeptember 12th 2022
First results from the RADICALS-HD trial demonstrated improved metastasis-free survival with 2 years of androgen-deprivation therapy (ADT) plus radiotherapy in men with prostate cancer.
Pembrolizumab Plus Olaparib Did Not Improve PFS and OS in mCRPCSeptember 12th 2022
Result from the phase 3 KEYLINK-010 trial showed no statistically significant improvement in radiographic progression-free survival and overall survival when pembrolizumab and olaparib were used to treat molecularly unselected, previously treated metastatic castration-resistant prostate cancer vs novel hormonal agents.
Olaparib/Abiraterone Provides Long-Lasting Robust Clinical Benefit Vs Abiraterone in First-Line mCRPCSeptember 11th 2022
Patients with with metastatic castration-resistant prostate cancer continued to derive notable benefit from treatment with first-line olaparib plus abiraterone acetate and prednisone or prednisolone compared with abiraterone monotherapy.
Enzalutamide Plus Abiraterone Acetate and Prednisolone Not Recommended for mHSPCSeptember 11th 2022
Despite the combination of enzalutamide plus abiraterone acetate and prednisolone (AAP) falling short in patients with metastatic hormone-sensitive prostate cancer, although androgen deprivation therapy plus AAP resulted in a clinically meaningful overall survival benefit.
Selecting Between Doublet and Triplet Therapy in mCSPCSeptember 8th 2022
Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Case 2: Triplet Therapy in a 59-Year-Old Man With mCSPCSeptember 8th 2022
Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.
Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPCSeptember 6th 2022
Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.
Phillip H. Kuo, MD, PhD, Evaluates Future Research Surrounding PSMA-PET Parameters and Response to 177Lu-PSMA-617 in mCRPCSeptember 2nd 2022
Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.
PSA Screening Associated With Prostate Cancer–Specific Mortality Risk Reduction Among Black and White US VeteransSeptember 2nd 2022
Findings from a study revealed a notable reduction in the risk of prostate cancer–specific mortality in Black United States veterans who underwent prostate-specific antigen screening, highlighting the potential importance of undergoing annual screenings in this patient population.
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPCAugust 31st 2022
In an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.
Baseline Benign Prostatic Hyperplasia Symptoms Warrant Consideration When Choosing Treatment in Early-Stage Prostate CancerAugust 31st 2022
Investigators highlighted that when determining a treatment strategy for patients with early-stage prostate cancer, baseline benign prostate hyperplasia symptoms should be taken into consideration.
Phillip H. Kuo, MD, PhD, Examines Utility of PSMA-PET Parameters to Predict Response to 177Lu-PSMA-617 in mCRPCAugust 29th 2022
Phillip H. Kuo, MD, PhD, spoke about how prostate-specific membrane antigen PET scan testing affected outcomes in patients with metastatic castration-resistant prostate cancer.
Ian D. Davis, MBBS, PhD, Reviews Interesting Data From TheraP Trial of 177Lu-PSMA-617 in mCRPC at 2022 ASCOAugust 29th 2022
Ian D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.
E. David Crawford, MD, Reviews the Evolution of Treatment for mHSPC Leading to the FDA Approval of Darolutamide, Chemo, and ADTAugust 26th 2022
In light of the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, E. David Crawford, MD, discussed the research that paved the way for the regulatory decision and where future efforts need to be focused.
Metastatic CSPC: Rationale Behind ADT + Apalutamide TherapyAugust 24th 2022
Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.
Toxicities and Drug-Drug Interactions With Frontline Therapies for mCSPCAugust 18th 2022
A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.
Factors in Selecting Frontline Therapy for Patients With mCSPCAugust 18th 2022
Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.
FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR StatusAugust 16th 2022
Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.